Pixel CO 2 Laser for the Treatment of Stress Urinary Incontinence: A Prospective Observational Multicenter Study.
Autor: | Franić D; Faculty of Medicine, University of Maribor, Maribor, Slovenia.; Outpatient Clinic Ob&Gyn, Slatina, Slovenia., Fistonić I; Clinic Ob/Gyn, Zagreb, Croatia.; Medical School University of Rijeka, Croatia., Franić-Ivanišević M; Health Center Slovenske Konjice, OB&Gyn Unit, Slovenske Konjice, Slovenia., Perdija Ž; CIIM Plus, Medical Center, Maribor, Slovenia., Križmarić M; Faculty of Medicine, University of Maribor, Maribor, Slovenia.; Faculty of Health Sciences, University of Maribor, Maribor, Slovenia. |
---|---|
Jazyk: | angličtina |
Zdroj: | Lasers in surgery and medicine [Lasers Surg Med] 2021 Apr; Vol. 53 (4), pp. 514-520. Date of Electronic Publication: 2020 Sep 08. |
DOI: | 10.1002/lsm.23319 |
Abstrakt: | Background and Objectives: Energy-based treatments have been found to be a promising treatment modality for improving stress urinary incontinence (SUI) symptoms. This prospective two-center study was designed to evaluate the efficacy of fractional-pixel CO Study Design/materials and Methods: Eighty-five women with SUI symptoms as per the cough stress test and validated International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF), were treated intravaginally with Pixel-CO Results: The ICIQ-UI-SF score was 12.0 at baseline, 7.0, after the first treatment, and 3.5 after the second treatment (P = 0.001). For women with BMI (25.0-29.9), the ICIQ-UI-SF score was 9.0 at the baseline, 6.0 after 1 month, and 5.0 at the 6 months follow-up visit (P = 0.04). For women with BMI ≥ 30.0, the ICIQ-UI-SF score was reduced from 14.0 to 8.0 1 month after the baseline and 5.0 at the 6-month follow-up visit (P = 0.001). SUI severity evaluation at baseline showed that 27.1% of women had mild, 24.7% had moderate, 45.9% had severe, and 2.4% had very severe SUI symptoms. SUI severity scores were significantly reduced, with 45.8% of women with no SUI symptoms, 18.8% with mild, 20.8% with moderate, and 14.6% with severe SUI symptoms at the 6-month follow-up. The patient's evaluation of VAS after the first treatment was 1.0-1.5 (0-10) and 0.0 1 week after the second treatment. Conclusion: Fractional-pixel CO (© 2020 Wiley Periodicals LLC.) |
Databáze: | MEDLINE |
Externí odkaz: |